Indications
Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.
Composition
- Active substance
- lesinurad
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zurampic
- Active substance
- lesinurad
- ATC code
- M04AB05
- Therapeutic area
- Hyperuricemia
- Marketing authorisation holder
- Grünenthal GmbH
- Status
- Withdrawn